“Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling,” US Treasury Website, April 23, 2026

Following the final order issued by the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) to reschedule certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act (CSA), the U.S. Department of the Treasury and the Internal Revenue Service (IRS) issued a press release on April 23, 2026, detailing the forthcoming tax guidance. This administrative shift carries substantial tax implications for clients operating in the cannabis space, directly impacting the application of the deduction disallowance under Section 280E of the Internal Revenue Code (I.R.C.).

For tax practitioners, analyzing the Treasury's initial statements against the DEA’s regulatory recommendations is critical for effective tax planning in the coming filing seasons.

The Foundational Shift in I.R.C. § 280E Applicability

Historically, state-licensed cannabis businesses have been severely restricted by I.R.C. § 280E, which mandates that "[n]o deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted".

Because the DOJ's Final Order transfers FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical license to Schedule III, the fundamental trigger for I.R.C. § 280E is removed for these specific operations. Treasury and the IRS formally recognized this in their April 23, 2026 release, stating that "rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA". The agencies anticipate this will yield "significant positive tax consequences for businesses in the medical marijuana industry".

Forthcoming Guidance on Expense Apportionment for Multiple Activities

One of the most complex issues practitioners will face is advising clients that engage in both medical and adult-use (recreational) cannabis operations, or those handling both state-licensed retail products and unlicensed bulk crops. The DOJ order explicitly leaves "unlicensed marijuana crops, bulk marijuana, and any marijuana and marijuana extract that has not yet been incorporated into a FDA-approved drug product in Schedule I".

Consequently, a single enterprise may simultaneously engage in Schedule I trafficking (subject to I.R.C. § 280E) and Schedule III distribution (exempt from I.R.C. § 280E). The Treasury press release directly addresses this bifurcation, noting that forthcoming guidance will "clarify the ways in which, for businesses with multiple activities, section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances (e.g., by apportioning expenses)". Tax professionals should anticipate complex cost-accounting regulations dictating how overhead, rent, and payroll must be allocated between Schedule I and Schedule III revenue streams, moving beyond the traditional Cost of Goods Sold (COGS) calculations previously relied upon under I.R.C. § 471.

Transition Rules and the Effective Date

For tax planning purposes, the timing of these changes is paramount. The Treasury intends to issue a transition rule to simplify the application of I.R.C. § 280E for the year the final order takes effect. According to the press release, the guidance is "expected to include a transition rule providing that, for purposes of section 280E, rescheduling generally will be considered to first apply for a business's full taxable year that includes the effective date of the Final Order, for the business's activities that do not involve Schedule I or II controlled substances as a result of the Final Order".

This represents a highly taxpayer-favorable approach. Rather than requiring practitioners to cut off and bifurcate the tax year precisely on the April 22, 2026 effective date of the DOJ order, the IRS intends to allow qualifying medical marijuana businesses to operate free from I.R.C. § 280E restrictions for the entirety of the taxable year in which the order becomes effective.

Comparing Treasury's Approach to the DEA’s Recommendations

While the Treasury's full-year transition rule is generous for the current tax year, it falls short of the specific regulatory relief suggested by the DEA in the text of the Final Order.

In the final rule (Docket No. DEA-XXXX), the DEA Administrator included a targeted recommendation to the Treasury regarding past tax liabilities. The order states: "The Administrator encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license".

Despite this explicit encouragement from the DEA to forgive or refund prior-year tax liabilities for medical operators, the Treasury press release is entirely silent on the prospect of retrospective relief. The Treasury’s announced "transition rule" is strictly prospective—applying only to the "business's full taxable year that includes the effective date" and presumably future years.

This divergence is consistent with the strict statutory interpretation typical of the IRS. Because the controlled substances were legally classified as Schedule I prior to April 2026, the statutory requirements of I.R.C. § 280E were met during those prior years. The DEA acknowledged its lack of authority over these tax matters in the Final Order, embedding a formal disclaimer: "Nothing in this rule constitutes a determination regarding federal tax liability, and state licensees should consult with tax counsel regarding the applicability of Section 280E to their specific circumstances".

Conclusion

Tax practitioners must vigilantly monitor the Internal Revenue Bulletin for the official publication of these regulations. While the promised transition rule will allow a full year of deductions for the 2026 tax year for qualifying entities, practitioners should not prematurely amend prior-year returns claiming retrospective relief, as the Treasury has not yet indicated any willingness to adopt the DEA’s recommendation for retroactive I.R.C. § 280E forgiveness. Furthermore, CPAs and EAs must begin preparing robust apportionment methodologies for clients operating mixed medical and recreational facilities, as the IRS will mandate strict segregation of expenses between Schedule I and Schedule III activities.

Prepared with assistance from NotebookLM.